Downloads
Download data is not yet available.
Abstract
Locally advanced gastric cancer poses a significant challenge in oncology due to its aggressive nature and limited treatment options. Neo-adjuvant chemotherapy, an innovative therapeutic approach, has emerged as a potential strategy to improve outcomes for patients with locally advanced gastric cancer. This comprehensive review aims to assess the efficacy of neo-adjuvant chemotherapy in the management of locally advanced gastric cancer, shedding light on its impact on tumor response, survival rates, and treatment-related adverse events.
The review systematically analyzes the existing literature, encompassing randomized controlled trials, cohort studies, and meta-analyses, to collate evidence on the effectiveness of neo-adjuvant chemotherapy. Key factors such as patient selection criteria, chemotherapeutic agents, treatment regimens, and response assessment criteria are evaluated to provide a detailed overview of the current state of research in this field.
The findings from this comprehensive review highlight the potential benefits of neo-adjuvant chemotherapy in downstaging locally advanced gastric tumors, facilitating curative resections, and potentially improving long-term survival rates. Moreover, the review explores the challenges associated with this treatment approach, including treatment-related toxicity, patient tolerance, and optimal sequencing with other treatment modalities.
The review also discusses ongoing research efforts, emerging trends, and future directions in the realm of neo-adjuvant chemotherapy for locally advanced gastric cancer. Understanding the nuances of this treatment approach is crucial for optimizing patient outcomes and guiding clinical decision-making.
Keywords:
Neo-adjuvant chemotherapy, locally advanced gastric cancer, efficacy
References
D.T. Dempsey, Stomach, in: F.C. Brunicardi, D.K. Andersen, T.R. Billiar, D.L. Dunn, J.G. Hunter, J.B. Matthews, et al. (Eds.), Schwartz's Principles of Surgery, McGraw-Hill, New York, 2010, pp. 931e935.
D.M. Mahvi, S.B. Krantz, Stomach, in: C.M. Townsend, R.D. Beauchamp, M. Evers, K.L. Mattox (Eds.),Sabiston Textbook of Surgery, Elsevier Saunders, New York, 2012, pp. 1198e1217.
J.T. Langell, S.J. Mulvihill, Gastric adenocarcinoma and other gastric neoplasms (except gastrointestinal stromal tumors), in: M.J. Zinner, Ashley (Eds.), Maingot's Abdominal Operations, McGraw-Hill, China, 2013, pp. 463e488.
S.H. Patel, D.A. Kooby, Gastric adenocarcinoma surgery and adjuvant therapy, Surg. Clin. N. Am. 91 (5) (2011) 1039e1077.
H.H. Hartgrink, C.J. van de Velde, H. Putter, I. Songun, M.E. Tesselaar, and E.K. Kranenbarg, et al., Neo-adjuvant chemotherapy for operable gastriccancer: long term results of the Dutch randomised FAMTX trial, Eur. J. Surg.Oncol. 30 (6) (2004) 643e649.
M.L. Hansen, E. Fallentin, C. Lauridsen, I. Law, B. Federspiel, L. Bæksgaard, et al., Computed tomography (CT) perfusion as an early predictive marker for treatment response to neoadjuvant chemotherapy in gastroesophageal junction cancer and gastric cancer e a prospective study, PLoS One 9 (5)(2014) e97605.
M.G. Guo, Q. Zheng, J. Zhong Di, Z. Yang, Histological complete response to a combined docetaxel/cisplatin/fluorouracil neoadjuvant chemotherapy for T4 stage gastric adenocarcinoma, World J. Surg.Oncol. 12 (1) (2014) 150.
E. Oki, Y. Emi, T. Kusumoto, Y. Sakaguchi, M. Yamamoto, N. Sadanaga, et al.,Phase II study of docetaxel andS-1 (DS) as neoadjuvant chemotherapy for clinical stage III resectable gastric cancer, Ann. Surg. Oncol. 21 (7)(2014)2340e2346.
P. Del Rio, M. Rocchi, P. Dell'Abate, F. Pucci, C. Mazzetti, M. Sianesi, Advanced stage gastric cancer andNeoadjuvant chemotherapy: our experience in surgical resectability, Ann. Ital. Chir. 84 (6) (2013) 623e629.
T. Nagahama, M. Ando, R. Seki, K. Fujiya, H. Amagasa, J. Takasaki, et al., Preoperative chemotherapy for advanced gastric cancer, Gan To Kagaku Ryoho40 (12) (2013) 2217e2219.
A.M. Lowy, P.F. Mansfield, S.D. Leach, R. Pazdur, P. Dumas, J.A. Ajani, Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer, Ann. Surg. 229 (3) (1999) 303e308.
Kaptein AA, Morita S, Sakamoto J: Quality of life in gastric cancer.World J Gastroenterol 2005, 11:3189-3196.
